" class="no-js "lang="en-US"> Arpa Garay - Medtech Alert
Saturday, September 20, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Arpa Garay

Arpa Garay

About Arpa Garay

Senior healthcare executive with global general management experience across commercial P&L, corporate strategy, business development, data & analytics, and digital transformation. Five years of management consulting experience across various industries and business challenges. Recognized both externally and internally for leadership and business impact.

Related Story

COVID-19

 Swissmedic Authorizes Moderna’s Omicron-targeting Bivalent Booster Candidate

Swissmedic Authorizes Moderna’s Omicron-targeting Bivalent Booster Candidate, mRNA-1273.214

August 30 2022

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Appointments

 Arpa Garay Joins Moderna as Chief Commercial Officer | Pharmtech Focus

Arpa Garay Joins Moderna as Chief Commercial Officer

April 28 2022

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]